OBJECTIVE: The study objective was to estimate the prevalence and correlates of antidepressant use by black and white Americans. METHODS: Data from the Collaborative Psychiatric Epidemiology Surveys (CPES) were analyzed to calculate nationally representative estimates of past-year antidepressant use by black and white Americans ages 18 years and older (N=9,723). RESULTS: Among individuals with depressive and anxiety disorders in the past year (N=516), black respondents (14.6%) had significantly lower (p<.001) antidepressant use than white respondents (32.4%). Depression severity was significantly associated with higher antidepressant use for white but not for black respondents. Psychiatric disorders and vascular disease significantly increased the odds of past-year antidepressant use. The increased prevalence of antidepressant use associated with vascular disease was independent of diagnosable psychiatric disorders. Among respondents not meeting criteria for depressive and anxiety disorders in the past year, lifetime depressive and anxiety disorders and vascular disease significantly increased the odds of antidepressant use. CONCLUSIONS: Few white and fewer black Americans with depressive and anxiety disorders received antidepressant treatment. Higher depression severity was associated with more antidepressant use for white but not for black respondents. Antidepressant use was associated with medical conditions related to vascular disease, and these medical conditions were independent of coexisting psychiatric conditions. The results also indicate that many antidepressants are used for maintenance pharmacotherapy for depressive and anxiety disorders as well as common medical conditions associated with vascular disease.
OBJECTIVE: The study objective was to estimate the prevalence and correlates of antidepressant use by black and white Americans. METHODS: Data from the Collaborative Psychiatric Epidemiology Surveys (CPES) were analyzed to calculate nationally representative estimates of past-year antidepressant use by black and white Americans ages 18 years and older (N=9,723). RESULTS: Among individuals with depressive and anxiety disorders in the past year (N=516), black respondents (14.6%) had significantly lower (p<.001) antidepressant use than white respondents (32.4%). Depression severity was significantly associated with higher antidepressant use for white but not for black respondents. Psychiatric disorders and vascular disease significantly increased the odds of past-year antidepressant use. The increased prevalence of antidepressant use associated with vascular disease was independent of diagnosable psychiatric disorders. Among respondents not meeting criteria for depressive and anxiety disorders in the past year, lifetime depressive and anxiety disorders and vascular disease significantly increased the odds of antidepressant use. CONCLUSIONS: Few white and fewer black Americans with depressive and anxiety disorders received antidepressant treatment. Higher depression severity was associated with more antidepressant use for white but not for black respondents. Antidepressant use was associated with medical conditions related to vascular disease, and these medical conditions were independent of coexisting psychiatric conditions. The results also indicate that many antidepressants are used for maintenance pharmacotherapy for depressive and anxiety disorders as well as common medical conditions associated with vascular disease.
Authors: Steven G Heeringa; James Wagner; Myriam Torres; Naihua Duan; Terry Adams; Patricia Berglund Journal: Int J Methods Psychiatr Res Date: 2004 Impact factor: 4.035
Authors: James S Jackson; Myriam Torres; Cleopatra H Caldwell; Harold W Neighbors; Randolph M Nesse; Robert Joseph Taylor; Steven J Trierweiler; David R Williams Journal: Int J Methods Psychiatr Res Date: 2004 Impact factor: 4.035
Authors: Koen Demyttenaere; Ronny Bruffaerts; Jose Posada-Villa; Isabelle Gasquet; Viviane Kovess; Jean Pierre Lepine; Matthias C Angermeyer; Sebastian Bernert; Giovanni de Girolamo; Pierluigi Morosini; Gabriella Polidori; Takehiko Kikkawa; Norito Kawakami; Yutaka Ono; Tadashi Takeshima; Hidenori Uda; Elie G Karam; John A Fayyad; Aimee N Karam; Zeina N Mneimneh; Maria Elena Medina-Mora; Guilherme Borges; Carmen Lara; Ron de Graaf; Johan Ormel; Oye Gureje; Yucun Shen; Yueqin Huang; Mingyuan Zhang; Jordi Alonso; Josep Maria Haro; Gemma Vilagut; Evelyn J Bromet; Semyon Gluzman; Charles Webb; Ronald C Kessler; Kathleen R Merikangas; James C Anthony; Michael R Von Korff; Philip S Wang; Traolach S Brugha; Sergio Aguilar-Gaxiola; Sing Lee; Steven Heeringa; Beth-Ellen Pennell; Alan M Zaslavsky; T Bedirhan Ustun; Somnath Chatterji Journal: JAMA Date: 2004-06-02 Impact factor: 56.272
Authors: Jay M Pomerantz; Stan N Finkelstein; Ernst R Berndt; Amy W Poret; Leon E Walker; Robert C Alber; Vidya Kadiyam; Mitali Das; David T Boss; Thomas H Ebert Journal: J Clin Psychiatry Date: 2004-03 Impact factor: 4.384
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Steven Z Chao; Brandy R Matthews; Jennifer S Yokoyama; Ngan Betty Lai; Hilary Ong; Marian Tse; Runfen Frances Yuan; Amy Lin; Joel Kramer; Kristine Yaffe; John Kornak; Bruce L Miller; Howard J Rosen Journal: Am J Geriatr Psychiatry Date: 2013-09-08 Impact factor: 4.105
Authors: Charles A Hall; Kevin M Simon; Eric J Lenze; Mary Amanda Dew; Amy Begley; Meryl A Butters; Daniel M Blumberger; Jacqueline A Stack; Benoit Mulsant; Charles F Reynolds Journal: Psychiatr Serv Date: 2015-08-17 Impact factor: 3.084
Authors: Shun-Chiao Chang; Wei Wang; An Pan; Richard N Jones; Ichiro Kawachi; Olivia I Okereke Journal: Am J Geriatr Psychiatry Date: 2016-08-05 Impact factor: 4.105